Zhang Y, Yan H, Xu Z, Yang B, Luo P, He Q (2019) Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. Expert Opin Drug Metab Toxicol 15(9):767–774. https://doi.org/10.1080/17425255.2019.1663169

Article  CAS  PubMed  Google Scholar 

He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B (2021) Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425. https://doi.org/10.1038/s41392-021-00828-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ (2017) A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 31(6):820–832e823. https://doi.org/10.1016/j.ccell.2017.04.013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JS, Banerji U (2017) Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther 172:101–115. https://doi.org/10.1016/j.pharmthera.2016.12.001

Article  CAS  PubMed  Google Scholar 

Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach A, Luke RW, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L (2013) Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin– 4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56(5):2059–2073. https://doi.org/10.1021/jm301762v

Article  CAS  PubMed  Google Scholar 

Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M (2012) Preclinical Pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11(4):873–887. https://doi.org/10.1158/1535-7163.Mct-11-0824-t

Article  CAS  PubMed  Google Scholar 

Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden T-A, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ (2020) Fulvestrant plus Capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 21(3):345–357. https://doi.org/10.1016/S1470-2045(19)30817-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH, Hall P, Perren T, Stein RC, László M, Ferrero J-M, Phillips M, Conibear J, Sarker S-J, Prendergast A, Cartwright H, Mousa K, Turner NC (2018) AZD5363 plus Paclitaxel versus placebo plus Paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. J Clin Oncol 36(15 Suppl):1007. https://doi.org/10.1200/JCO.2018.36.15_suppl.1007

Article  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS (2023) Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388(22):2058–2070. https://doi.org/10.1056/NEJMoa2214131

Article  CAS  PubMed  PubMed Central  Google Scholar 

AstraZeneca Pharmaceuticals LP (2023) Highlights of prescribing information. TRUQAP™ (capivasertib) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Accessed December 18, 2024

European Commission (2024) Union Register of medicinal products for human use. Truqap. https://ec.europa.eu/health/documents/community-register/html/h1820.htm. Accessed 2 September, 2024

AstraZeneca Canada Inc (2024) Product monograph. Truqap, capivasertib tablets. https://pdf.hres.ca/dpd_pm/00074395.PDF. Accessed 2 September, 2024

Australian Product Information, Truqap (2024) (capivasertib). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id?CP-2024-PI-01864-1&d?20240612172310101&d?20240902172310101. Accessed 2 September, 2024

AstraZeneca AG (2024) Truqap, Filmtabletten. 2024. https://www.swissmedicinfo.ch/ViewMonographie. Accessed 2 September, 2024

Pharmaceuticals and Medical Devices Agency (2024) New Drugs Approved in FY 2023. https://www.pmda.go.jp/files/000269225.pdf. Accessed 2 September, 2024

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro M, Bajpai J, Barrios C, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso M, Carey L, Mac Gregor M, Chidebe R, Cortés J, Curigliano G, Dent R, El Saghir N, Eniu A, Fallowfield L, Francis P, Franco Millan S, Gilchrist J, Gligorov J, Gradishar W, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim S-B, Koppikar S, Kuper-Hommel M, Lecouvet F, Mason G, Mertz S, Mueller V, Myerson C, Neciosup S, Offersen B, Ohno S, Pagani O, Partridge A, Penault-Llorca F, Prat A, Rugo H, Senkus E, Sledge G, Swain S, Thomssen C, Vorobiof D, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer E (2024) 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76:103756. https://doi.org/10.1016/j.breast.2024.103756

Article  PubMed  PubMed Central  Google Scholar 

Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Testing ftB, Endocrine, Panels TTMBCE, Henry NL, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A, Burstein HJ, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS (2024) Endocrine and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer—capivasertib-fulvestrant: ASCO rapid recommendation update. J Clin Oncol 42(12):1450–1453. https://doi.org/10.1200/jco.24.00248

Article  CAS  PubMed  Google Scholar 

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM (2018) A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res 24(9):2050–2059. https://doi.org/10.1158/1078-0432.Ccr-17-2260

Article  CAS  PubMed  Google Scholar 

Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, Hirai F, Arita S, Toyokawa G, Chen L, Yamamoto H, Kawata T, Lindemann J, Esaki T (2016) Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77(4):787–795. https://doi.org/10.1007/s00280-016-2987-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do K-A, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F (2019) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78. https://doi.org/10.1186/s13058-019-1154-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sternberg CN, Bracarda S, de Bono JS, Sweeney C, Chi KN, Olmos D, Sandhu SK, Massard C, Garcia J, Schenkel F, Chen G, Harris A, Hinton H, Matsubara N (2021) 585P safety analysis of the phase III IPATential150 trial of Ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 32:S635–S636. https://doi.org/10.1016/j.annonc.2021.08.1098

Article  Google Scholar 

Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor Alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31(8):1001–1010. https://doi.org/10.1016/j.annonc.2020.05.001

Article  CAS  PubMed  Google Scholar 

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gomez Villanueva A, Perez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M (2019) BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor Capivasertib (AZD5363) combined with Paclitaxel in patients with Estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol 30(5):774–780. https://doi.org/10.1093/annonc/mdz086

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH (2022) Fulvestrant plus Capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 23(7):851–864. https://doi.org/10.1016/S1470-2045(22)00284-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Pass M, Rowlands V, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM (2020) Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer. Clin Cancer Res 26(15):3947–3957. https://doi.org/10.1158/1078-0432.Ccr-19-3953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, Bailey C, Casson E, Cripps D, Cullberg M, Evans S, Foxley A, Lindemann J, Rugman P, Taylor N, Turner G, Yates J, Lawrence P (2018) A phase 1, open-label, multicentre study to compare the capsule and tablet formu